Lpath said that the first patent (US 7,829,674) contains claims covering the composition of matter for its anti-Sphingosine-1-Phosphate (S1P) antibody, sonepcizumab, the active component in Lpath’s two lead compounds, iSONEP and ASONEP.
The second patent (US 7,794,713) is a method-of-use patent, with claims covering the use of anti-S1P antibodies for treating S1P-associated hyperproliferative diseases associated with aberrant cardiac remodeling, such as cardiac failure and restenosis.
Lpath Intellectual Property executive director Laurel Bernstein said that the USPTO has validated the novelty and utility of Lpath’s S1P-neutralising monoclonal antibodies and their use in the treatment of a range of diverse diseases and conditions.
Lpath CEO Scott Pancoast said that with the issuance of these two patents, their lead programs are further protected, enhancing their commercial value over time.